Revance Therapeutics Inc (RVNC)
5.80
-0.10
(-1.69%)
USD |
NASDAQ |
Nov 01, 16:00
5.795
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Gross Profit Margin (Quarterly): 73.03% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 73.03% |
| March 31, 2024 | 71.29% |
| December 31, 2023 | 74.97% |
| September 30, 2023 | 65.81% |
| June 30, 2023 | 67.64% |
| March 31, 2023 | 72.72% |
| December 31, 2022 | 52.90% |
| September 30, 2022 | 63.00% |
| June 30, 2022 | 66.43% |
| Date | Value |
|---|---|
| March 31, 2022 | 68.75% |
| December 31, 2021 | 69.63% |
| September 30, 2021 | 70.19% |
| June 30, 2021 | 71.14% |
| March 31, 2021 | 68.29% |
| December 31, 2020 | 67.10% |
| September 30, 2020 | 71.71% |
| June 30, 2020 | 92.98% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
52.90%
Minimum
Dec 2022
92.98%
Maximum
Jun 2020
69.86%
Average
69.63%
Median
Dec 2021
Gross Profit Margin (Quarterly) Benchmarks
| Recursion Pharmaceuticals Inc | 36.14% |
| Moderna Inc | 47.96% |
| Pacira BioSciences Inc | 75.14% |
| PetIQ Inc | 26.84% |
| Anebulo Pharmaceuticals Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -55.05% |
| Return on Invested Capital | -87.72% |
| Profit Margin (Quarterly) | -57.31% |
| Operating Margin (Quarterly) | -52.79% |
| Return on Net Operating Assets | -149.3% |